The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Applying quality improvement methodologies to decrease the time-to-activation of new clinical trials at an NCI-designated comprehensive cancer center.
 
Timothy J Brown
No Relationships to Disclose
 
Erin Fenske Williams
Consulting or Advisory Role - Lilly
Travel, Accommodations, Expenses - Lilly
 
Patrice Griffith
No Relationships to Disclose
 
Asal Shoushtari Rahimi
No Relationships to Disclose
 
Rhonda Oilepo
No Relationships to Disclose
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; exelixis; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Theodore Willis Laetsch
Consulting or Advisory Role - Bayer; Lilly; Loxo; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Jubilant Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); Novella Clinical (Inst); Pfizer (Inst); SERVIER (Inst)
 
Pamela Kurian
No Relationships to Disclose
 
Penny Currykosky
Employment - Abbvie
 
Susan Partridge
No Relationships to Disclose
 
Muhammad Shaalan Beg
Consulting or Advisory Role - Array BioPharma; Boston Biomedical; Celgene; Genentech/Roche; Guardant Health; Ipsen
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche; Ipsen
Research Funding - Agios (Inst); ArQule (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); MedImmune (Inst); Merck Serono (Inst); Sillajen (Inst); Tolero Pharmaceuticals (Inst)